An Ascendant Challenge: Central Nervous System Metastases in ALK+ Lung Cancers.
Yonina R Murciano-GoroffGuilherme HaradaAlexander E DrilonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Central nervous system (CNS) metastases constitute a challenge for the design of anaplastic lymphoma kinase (ALK) fusion-positive lung cancer trials. The ASCEND-7 study of ceritinib demonstrates the feasibility of broadening CNS eligibility criteria to include symptomatic brain and leptomeningeal disease and highlights design features that contemporary trials will need to incorporate. See related article by Chow et al., p. 2506.